| A comparison of five epidemiological models for transmission of SARS-CoV-2 in India S Purkayastha, R Bhattacharyya, R Bhaduri, R Kundu, X Gu, M Salvatore, ... BMC infectious diseases 21, 1-23, 2021 | 54 | 2021 |
| A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19 Y Ray, SR Paul, P Bandopadhyay, R D’Rozario, J Sarif, D Raychaudhuri, ... Nature Communications 13 (1), 383, 2022 | 35 | 2022 |
| Estimating the wave 1 and wave 2 infection fatality rates from SARS-CoV-2 in India S Purkayastha, R Kundu, R Bhaduri, D Barker, M Kleinsasser, D Ray, B Mukherjee BMC Research Notes 14 (262), 7, 2021 | 32* | 2021 |
| Incorporating false negative tests in epidemiological models for SARS-CoV-2 transmission and reconciling with seroprevalence estimates R Bhattacharyya, R Kundu, R Bhaduri, D Ray, LJ Beesley, M Salvatore, ... Scientific reports 11 (1), 9748, 2021 | 23 | 2021 |
| Reconciling epidemiological models with misclassified case-counts for SARS-CoV-2 with seroprevalence surveys: a case study in Delhi, India R Bhattacharyya, R Bhaduri, R Kundu, M Salvatore, B Mukherjee MedRxiv, 2020.07. 31.20166249, 2020 | 23 | 2020 |
| Extending the Susceptible-Exposed-Infected-Removed (SEIR) model to handle the high false negative rate and symptom-based administration of COVID-19 diagnostic tests: SEIR-fansy R Bhaduri, R Kundu, S Purkayastha, M Kleinsasser, LJ Beesley, ... MedRxiv, 2020 | 19 | 2020 |
| COVID-19 pandemic in India: through the lens of modeling GR Babu, D Ray, R Bhaduri, A Halder, R Kundu, GI Menon, B Mukherjee Global Health: Science and Practice 9 (2), 220-228, 2021 | 16 | 2021 |
| Extending the susceptible‐exposed‐infected‐removed (SEIR) model to handle the false negative rate and symptom‐based administration of COVID‐19 diagnostic tests: SEIR‐fansy R Bhaduri, R Kundu, S Purkayastha, M Kleinsasser, LJ Beesley, ... Statistics in medicine 41 (13), 2317-2337, 2022 | 14 | 2022 |
| SARS-CoV-2 infection fatality rates in India: systematic review, meta-analysis and model-based estimation L Zimmermann, S Bhattacharya, S Purkayastha, R Kundu, R Bhaduri, ... Studies in Microeconomics 9 (2), 137-179, 2021 | 11 | 2021 |
| Circulating interleukin-8 dynamics parallels disease course and is linked to clinical outcomes in severe COVID-19 R D’Rozario, D Raychaudhuri, P Bandopadhyay, J Sarif, P Mehta, ... Viruses 15 (2), 549, 2023 | 7 | 2023 |
| Estimating the infection fatality rate from SARS-CoV-2 in India B Mukherjee, S Purkayashtha, R Kundu, R Bhaduri Available at SSRN 3798552, 2021 | 6 | 2021 |
| A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nat Commun. 2022; 13: 383 Y Ray, SR Paul, P Bandopadhyay, R D’Rozario, J Sarif, D Raychaudhuri, ... | 5 | |
| Clinical trial subgroup analyses to investigate clinical and immunological outcomes of convalescent plasma therapy in severe COVID-19 D Raychaudhuri, P Bandopadhyay, R D’Rozario, J Sarif, Y Ray, SR Paul, ... Mayo Clinic Proceedings: Innovations, Quality & Outcomes 6 (6), 511-524, 2022 | 4 | 2022 |
| Rough-Fuzzy CPD: a gradual change point detection algorithm R Bhaduri, S Roy, SK Pal Journal of Data, Information and Management 4 (3), 243-266, 2022 | 3 | 2022 |
| Author Correction: Incorporating false negative tests in epidemiological models for SARS-CoV-2 transmission and reconciling with seroprevalence estimates R Bhattacharyya, R Kundu, R Bhaduri, D Ray, LJ Beesley, M Salvatore, ... Scientific reports 11, 2021 | 1 | 2021 |
| Circulating Interleukin-8 Dynamics Parallels Disease Course and Is Linked to Clinical Outcomes in Severe COVID-19. Viruses 2023, 15, 549 R D’Rozario, D Raychaudhuri, P Bandopadhyay, J Sarif, P Mehta, ... | | 2023 |
| Onset detection: A new approach to QBH system R Bhaduri, S Bonnerjee, S Roy arXiv preprint arXiv:1908.07409, 2019 | | 2019 |
Ritoban KunduPhD Candidate, Department of Biostatistics, University of Michigan, Ann ArborEmail verificata su umich.edu